The remarkable efficacy of L-dopa on the akinesia, tremor and rigidity of Parkinson's disease
is incontestable. It is responsible for the functional improvement and the regained quality of
life. Unfortunately, after this classical" honeymoon" appear the" motor complications of
dopamine therapy"(MCD), motor fluctuations and dyskinesia. Even more frequent and
severe when the patient is young, it compromises the patient's autonomy. Certainly, the
manipulation of L-dopa, the modification of its metabolism, and its association with an …

Introduction To date, no drug has demonstrated clinically indisputable neuroprotective
efficacy in Parkinson's disease (PD). We also have no effective symptomatic treatment for
disabling symptoms such as balance problems, and dementia, and we need to improve the
efficacy and safety profile of drugs currently used in the management of motor complications.
Areas covered We examine the agents which appear to have most therapeutic promise
based on concepts, feasibility in a reasonable time frame, and available clinical data and …